Medical Professionals Reference (MPR)Anticoagulant Reversal Agent Andexxa Removed From the Market

The FDA removed anticoagulant reversal agent Andexxa from US market after postmarketing trial showed doubled thrombosis risk and nearly tripled thrombosis-related deaths. Approved in 2018 for reversing rivaroxaban/apixaban bleeding, the drug demonstrated 14.6% thrombosis rate versus 6.9% with usual care—with 53% of clots occurring within first 3 days of treatment.

⚖️ PROFESSIONAL IMPACT

• Accelerated approval pathway failed to detect life-threatening safety signal until 7 years post-market, exposing patients to 2.5% thrombosis-related mortality versus 0.9% with standard care
• Primary endpoint met but clinically hollow—hemostasis improvement driven by hematoma volume imaging, not meaningful clinical outcomes like stroke scores or rescue therapy reduction
• No FDA-approved reversal agent now exists for factor Xa inhibitor bleeding emergencies, forcing return to off-label strategies (prothrombin complex concentrates, tranexamic acid)
• Medicolegal exposure for institutions that adopted Andexxa as standard protocol—documentation of clinical equipoise and consent processes now critical for retrospective review

🎯 ACTION ITEMS

• Remove Andexxa from institutional formularies and acute bleeding protocols by December 22, 2025
• Update anticoagulation reversal guidelines to reflect return to 4-factor PCC as primary strategy for life-threatening bleeding
• Document informed consent discussions with patients on factor Xa inhibitors, noting absence of specific reversal agent
• Review recent Andexxa cases for thrombotic complications requiring disclosure or follow-up monitoring

For Further Reading